ImClone Delays Filing for Added Erbitux Approval (Reuters)
Reuters - ImClone Systems Inc. said on Tuesday
it will seek U.S. approval for its colon cancer drug Erbitux to
treat head and neck cancer by the end of this year, pushing
back its previous timeline.
Stumble It!
Tweet This
Bookmark on Delicious
Share on Facebook
Share on MySpace